IPL 550260

Drug Profile

IPL 550260

Alternative Names: IPL 550,260

Latest Information Update: 07 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inflazyme Pharmaceuticals
  • Class Anti-inflammatories
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 07 Feb 2017 Discontinued - Phase-I for Inflammation in Canada (PO)
  • 17 Mar 2006 Suspended - Phase-I for Inflammation in Canada (PO)
  • 13 Jul 2004 Inflazyme has completed phase Ib studies in inflammation in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top